Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Pomalidomide, rituximab, and orelabrutinib in combination with polatuzumab vedotin for newly diagnosed diffuse large B-cell lymphoma in elderly, unfit, or frail patients:a prospective phase II study

View Full Paper
Ask AI
Bookmark
Share

Authors

CQChangju QuSoochow UniversityFXFan XiaFudan University Shanghai Cancer CenterRZRui ZouXi'an University of Science and Technology

Discussion

Loading...

Member takes

Implication

Phase II study shows promising efficacy of PRO-Pola regimen in elderly DLBCL patients, suggesting improved outcomes and safety.

Key Points

  • This research aims to evaluate the efficacy and safety of the PRO-Pola regimen for treating elderly, unfit, or frail patients with newly diagnosed diffuse large B-cell lymphoma.
  • Open-label, single-arm, phase II study with elderly patients (aged ≥70 years)
  • Participants received induction therapy with pomalidomide, rituximab, and orelabrutinib for one cycle
  • Those achieving minimal response received additional cycles of the PRO-Pola regimen including polatuzumab vedotin
  • Endpoints included complete response rate (CRR), overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety monitoring.
  • 100% of patients achieved at least a minimal response after PRO induction therapy
  • CRR of 77.8% and ORR of 100% after the PRO-Pola regimen
  • Both CRR and ORR reached 100% among patients completing all 6 cycles
  • Adverse events occurred in 92.9% of patients, with 50% experiencing grade ≥3 events
  • All toxicities reported were transient and reversible.

Cite This Study

Qu et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d647https://doi.org/10.1182/blood-2025-1912
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Polatuzumab vedotin combined with orelabrutinib and rituximab (PRO Regimen) as frontline therapy in elderly and frail patients with diffuse large B-cell lymphoma (DLBCL): Results from A phase II study2025
  2. 2Efficacy and safety of the polatuzumab, acalabrutinib, rituximab, and lenalidomide (Pola-AR2) regimen as first-line therapy in unfit or frail patients with diffuse large B-cell lymphoma2025
  3. 3Real-world outcomes of polatuzumab, rituximab, and lenalidomide in frail pts with diffuse large B-cell lymphoma.2026
  4. 4Phase 2 Study of polatuzumab vedotin, zanubrutinib and rituximab (Pola-ZR) in untreated elderly and frail DLBCL patients: Molecular features and follow-up updates2025
  5. 5Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study2025